Introduction
Thrombocytopenia is common in neonatal intensive care units (NICU) . Approximately 20 to 30% of those admitted to a NICU will have thrombocytopenia. [1] [2] [3] In a retrospective study of 800 infants by Castle et al., 3 22% developed thrombocytopenia, with a platelet nadir occurring at day 4 of life. Critically ill infants and those born less than 37 weeks gestation are more likely to develop thrombocytopenia. 2 For example, in an analysis of 284 extremely low-birth-weight infants, 73% developed thrombocytopenia. 4 We previously demonstrated a potential benefit of using platelet mass rather than platelet number as an indication of platelet transfusion. A neonate with a mean platelet volume (MPV) of 8 fl and a platelet count of 50 000 ml À1 should have platelet plug generation hemostatically equivalent to a neonate with a count of 40 000 ml À1 and an MPV of 10 fl. 5 Therefore, it may be more physiological to use platelet mass, not platelet count, as an indicator for platelet transfusion. However, further studies are needed to test this theory.
The relationship between the incidence and severity of intraventricular hemorrhage (IVH) and thrombocytopenia is controversial. Studies conflict regarding whether a low platelet count is causal with IVH. Moreover, it is unclear whether prophylactic platelet transfusions can prevent IVH. As a step toward answering these questions, we performed the present analysis, seeking associations between platelet mass and common perinatal factors, including IVH.
Methods

Patients and design
The study consisted of a retrospective cohort of infants with birth weight less than 1500 g admitted to the NICU at Christiana Hospital from June 2003 through July 2006. The nursery at Christiana Hospital is the only level 3 NICU in the state of Delaware caring for both inborn (90%) and outborn infants. The Institutional Review Board at Christiana Care Health Services approved this research project. Data were obtained from a computerized database and review of the medical record. All data were entered into the database by trained reviewers and the database is periodically checked for errors.
Platelet mass was calculated from complete blood counts (CBCs) obtained for routine patient care as the product of the platelet number and the MPV. Complete blood counts were obtained on NICU admission and daily for the next 2 days. If the infant had more than one Complete blood counts obtained per day, the first of the day was used. The average MPV over the first 48 h was used, because the MPV did not change over this time and not every Complete blood counts had a reported MPV value. Platelet mass was compared with demographic variables including race, birth weight and gender. All infants had a cranial sonogram on day of life 4. Severe IVH was considered grade 3 to 4 based on the classification system of Papile. 6 Platelet mass was compared with IVH alone, severe IVH and IVH and/or death. For the purposes of this study, death was considered death before hospital discharge.
Platelet mass was investigated in relation to perinatal factors including: histological chorioamnionitis, intrauterine growth restriction (IUGR), steroid use and pre-eclampsia. Histological chorioamnionitis was determined by routine clinical pathology. IUGR was defined as a birth weight of less than the 10th percentile. Pre-eclampsia was diagnosed by the attending obstetrician and based on the American College of Obstetrics and Gynecology guidelines. 7 
Statistical analysis
Statistical analysis was performed using the Statistical software (Statistica v 7.0, Tulsa, OK, USA). Unadjusted analyses included w 2 -test, one way-analysis of variance and the Mann-Whitney U-test. Multivariable analysis performed included linear regression. The data are presented as mean±standard deviations. P-values <0.05 were considered significant.
Results
The study sample consisted of 408 VLBW infants admitted to the neonatal intensive care unit between June 2003 and July 2006. The sample population included 223 male and 185 female infants. The mean gestational age and birth weight were 27.9 ± 2.6 weeks and 998±286 g, respectively, 41% of the infants were African American, 47% were Caucasian and 7% infants were Hispanic. Gestational age was inversely associated with platelet mass. (R ¼ À0.19; P<0.01.) Race, birth weight and gender had no correlation with platelet mass (data not shown).
Infants born to mothers with pre-eclampsia had a smaller platelet mass, owing to a lower platelet count but a similar MPV. (Table 1) IUGR status had a similar effect. In contrast, histological chorioamnionitis was associated with a larger platelet mass (Table 1) , owing to higher platelet counts and MPV values. Antenatal maternal steroid administration was not associated with platelet mass. After controlling for gestational age, the three associations with platelet mass (IUGR, histological chorioamnionitis and pre-eclampsia) remained significant (P ¼ 0.01 for each). Table 2 demonstrates the variation of platelet mass, platelet count and MPV of the entire cohort over the first two days of life. Platelet mass is shown as the average value as well as the 10th and 90th percentile range. Table 3 shows the mean platelet mass, platelet count and MPV of the study cohort including those with or without IVH, severe IVH and/ or death at the time of NICU admission. Platelet mass at the time of admission, as well as the MPV and platelet count were similar to those who subsequently did vs did not develop IVH, severe IVH or death.
In order to determine if a low platelet mass during the first days of life was associated with IVH, we investigated the relationship between platelet mass in the lowest 10th percentile and IVH. Those who died and/or had severe IVH were more likely to have a platelet mass <10th percentile in the days following birth (Table 4 ). These differences in platelet mass were present on day of admission, DOL 1 and DOL 2. A large platelet mass (>90th percentile) was not associated with IVH, severe IVH and death and/or severe IVH. 11.0 ± 0.7 10.9 ± 0.8 0.4
Abbreviations: IUGR, intrauterine growth restriction; MPV, mean platelet volume. 
Discussion
In our population of VLBW infants, those infants with severe IVH were more likely to have a low platelet mass in first 2 days of life compared with infants without IVH. In addition, infants with IUGR, and those born to mothers with pre-eclampsia, had a reduction in platelet mass, whereas those infants born to mothers with histological chorioamnionitis had an increase in platelet mass. To our knowledge, our study is the first to investigate the association between platelet mass and IVH, and the first to investigate the perinatal factors influencing platelet mass. IUGR and pre-eclampsia are known to be associated with thrombocytopenia. 8, 9 The etiology of thrombocytopenia with both of these conditions may be related to placental insufficiency and/or fetal hypoxia. 9 Our data confirm these known associations showing a decrease in platelet number in IUGR infants and those infants born to mothers with pre-eclampsia. The reductions in platelet mass with IUGR and pre-eclampsia were due to lower platelet counts, because the MPV was not decreased with either condition. Because increased platelet production is usually associated with increased platelet volume, our data support other reports that pre-eclampsia and IUGR may lead to thrombocytopenia through platelet underproduction. Sepsis, as well as chorioamnionitis, have been associated with neonatal thrombocytopenia, and the MPV can increase with sepsis. [10] [11] [12] In those with histological chorioamnionitis, we observed a higher MPV. This finding suggests younger, larger platelets in the circulation during infection, which may be due to an increase in platelet production. 13 Although platelet mass has not been investigated in relation to IVH, thrombocytopenic infants have been found to have an increased risk of hemorrhage and have significantly greater mortality when compared with non-thrombocytopenic infants. 2 In a study by Andrew et al., 100 infants with platelet counts less than 100 000 were compared with non-thrombocytopenic infants. The platelet count and bleeding time were inversely related, with 60% of infants having an elevated bleeding time. The incidence of IVH and the severity of IVH were greater in the thrombocytopenic infants group. Infants with low platelet counts were also found to have more impaired neurological outcomes.
14 In contrast, Andrew et al., with 302 infants weighing less than 1500 g, showed a reduced platelet count was not associated with IVH. The severity of IVH did not correlate with thrombocytopenia. There was one randomized control trial of platelet transfusions in thrombocytopenic premature infants in preventing IVH. In this study, giving platelet transfusions to infants with a platelet count of less than 150 000 did shorten bleeding times but did not reduce the incidence or extent of IVH. 15 In our population of VLBW infants, those with IVH, severe IVH and severe IVH and/or death were more likely to have platelet mass <10th percentile in the first 2 days of life, but platelet mass did not differ on the day of birth. IVH in premature infants occurs within the first week of life, with the majority occurring within the first 4 days. As we can not determine the exact timing of IVH in these patients, we are unable to determine whether the low platelet mass preceded the IVH or was a result of the severe IVH and associated thrombus formation. As the platelet mass is an important hemostatic variable, it is biologically plausible that a low mass is causally associated with IVH. A low platelet mass has been shown to increase bleeding time in patients with chronic renal failure. Our data suggest that platelet mass may be an important clinical indicator of bleeding in premature infants, and platelet mass may be potentially important to consider in the decision to transfuse platelets. Currently, there are no universal guidelines to follow regarding platelet transfusions. Furthermore, platelet transfusions have been associated with adverse outcomes, including mortality. 4,17 -19 We recently demonstrated the feasibility and possible benefit of using platelet mass as an indicator for transfusion. [20] [21] Randomized studies are required before platelet mass is routinely used as a clinical indicator for transfusion in premature infants.
There are some important limitations to this study. Because our study is retrospective, the method and timing of obtaining complete blood counts were not standardized. There was potential for misclassification of IVH, as the diagnosis was determined based on clinical reading of cranial ultrasounds. However, this was minimized, as all cranial sonograms were read by pediatric radiologist from the same institution using the same classification system. In summary, pre-eclampsia and IUGR are associated with a smaller neonatal platelet mass, whereas histological chorioamnionitis is associated with a larger mass. Platelet mass on admission was the same in those infants with and without IVH. We did find an association with severe IVH and severe IVH and/or death with a small platelet mass within the first 2 days of life. Due to the association between a critical platelet mass and severe IVH, platelet mass could be used as a trigger for platelet transfusions. If it is feasible, than the number of platelet transfusions given to very low birth weight neonates may be reduced. In turn, the morbidity and mortality associated with platelet transfusions could decrease. Clearly, more work is needed to assess the value of the platelet mass calculation in neonatology, and to determine further relationship between platelet mass and neonatal outcomes.
